| Name | Title | Contact Details |
|---|
Based in Redmond, WA, EndoGastric Solutions, Inc., is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a minimally invasive solution that addresses a significant unmet clinical need.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Transitional Living and Community Support is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OSCOR Inc. designs, develops, manufactures and markets a variety of highly specialized implantable cardiac pacing leads, venous access systems and diagnostic catheters. Oscor is also leveraging its proprietary lead technologies toward the development
Innovative Neurotronics, Inc. is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.